Serious adverse events occurred in eight ( 7 % ) patients in the triple-treatment group and five ( 4 % ) in the dual-treatment group ( p = 0515 ) , and study drug discontinuations due to adverse events occurred in four ( 3 % ) in the triple-treatment group and one ( 1 % ) in the dual-treatment group ( p = 0223 ) .